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Abstract
Background: The objective of this paper is to summarise and critically review the available data about
onchocerciasis in Mozambique, in order to report epidemiological and clinical aspects related to the disease
and identify gaps in knowledge. The paper is intended to raise awareness of the existence and importance
of this disease and to define research priorities.
Methods: We examined the scarce epidemiological data at our disposal: two diagnostic studies in 1997 and
1998 (first reports on the existence of onchocerciasis in Mozambique), and two Rapid Epidemiological Mapping
of Onchocerciasis (REMO) surveys in 2001 and 2007. We examined differences in study designs and methodologies as
well as the differing geographical locations to explain the divergence in findings among the studies.
Results: Evidence indicates that onchocerciasis is hypoendemic in Mozambique (with national and imported cases),
but still largely remains an undiagnosed illness. There is no awareness of the clinical aspects of the disease and nor of
the differential diagnosis with lepromatous leprosy and dermatitis caused by Scabies spp. The use of skin biopsy and a
symptom screening questionnaire, combined with nodule rate, in the first two studies may have captured even
atypical or subacute presentations. Both REMO surveys relied solely on nodule detection and in the six years between
the two studies, the prevalence of nodules detected more than doubled.
Conclusions: The epidemiology and clinical aspects of the disease are unknown in Mozambique. Since the last REMO
took place in 2007 and since the population is subject to large-scale movement and displacement, it is important to
develop tools to identify and analyse populations that are at high risk for onchocerciasis. Cases of onchocerciasis may
be misdiagnosed as leprosy or scabies that fail to improve despite being subjected to treatment against leprosy.
Techniques to enable a differential diagnosis need to be established by training health professionals on the
recognition of this undiagnosed disease. It is equally necessary to identify the blackfly vectors and where they breed.
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Background
Onchocerciasis caused by Onchocerca volvulus is a
chronic cutaneous and ocular disease characterised by
skin nodules, severe itching, and ocular lesions that can
progress to partial or total blindness. It causes a great
morbidity and is the second leading cause of blindness
due to infectious disease worldwide. More than 99 % of
affected people live in Africa. It has been estimated that
21,115,000 members of the 118,285,000 African popula-
tion at risk for infection are infected. Among these,
690,000 experienced visual impairment and 220,000
were totally blind [1].
The vectors are dipterans of the family Simulidae,
known as blackflies, buffalo gnats or turkey gnats, al-
though there are more than a hundred other local names
throughout Africa. At least 26 members of the Simulium
damnosum Theobald complex are known in southern
and eastern Africa [2]. Blackflies become infected by* Correspondence: enoormahomed@gmail.com
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feeding on a person with microfilariae (mf) in the skin
(microfiladermia). Microfilariae develop to third stage
larvae, migrating to the blackfly labium and can pene-
trate the human skin through the fly bite. They become
adult in about one year, usually within the subcutaneous
nodules (onchocercomas) (0.5–10 cm or larger). The
onchocercomas include bundles of worms located in the
subcutaneous connective tissue, the juxta-articular areas,
and rarely in the muscles or bones. They are usually
painless, hard, and fibrous, mobile under the fingers
when palpated and rarely calcify. A patient may have
only one or many onchocercomas. Adult parasites can
be also found free under the subcutaneous tissue. Sev-
eral authors indicate that in African patients nodules are
located mainly on the trunk (especially on the hip area)
around the pelvis, particularly over the iliac crest, fem-
oral trochanter, coccyx, sacrum and lateral chest wall,
and on the limbs. But nodules can also be found in
the upper body, even in the head with percentages
that can reach over 30 %. Many head and upper body
nodules probably remain undetected in onchocerciasis
surveys [3].
Onchocerciasis is a systemic disease, as mf are distrib-
uted throughout the body; they can be found not only in
skin, eyes and lymph nodes, but also in the liver, kidney,
spleen, pancreas, lung, peripheral nerves and arteries.
Body fluids like blood, urine, hydrocele and vaginal
fluids, tears, cerebrospinal fluid and peritoneal may con-
tain microfilariae [4]. An association between microfila-
dermia and backache, body and joint pains has been
described; it also seems clear that persons with microfi-
ladermia weigh less than those without [5]. Highly in-
fected onchocerciasis patients are more likely to develop
the lepromatous form of leprosy, suggesting a striking
impairment of cell-mediated immunity [6].
An association of onchocerciasis and epilepsy was first
suggested in 1994 in Uganda [7], later in other African
countries. A meta-analysis including a total population of
79,270 individuals from ninety-one communities living in
seven countries (Benin, Nigeria, Cameroon, Central
African Republic, Uganda, Tanzania and Burundi) con-
cluded that onchocerciasis was associated with epilepsy
[8]. Onchocerciasis has also been associated with nodding
syndrome (NS), an epidemic epileptic encephalopathy af-
fecting thousands of children in Uganda, South Sudan and
Tanzania [9].
The psychological effects of onchocerciasis are also
very important as dermal lesions and lymph disorders
stigmatise and marginalise patients. The three compo-
nents of human health, physical, mental and social,
are strongly affected by this disease. Their individual
and social effects have been studied in communities
of south Nigeria [10]. A study revealed that oncho-
dermatitis was the main health problem of teenage
Nigerian girls as it reduced or eliminated their
chances to marry [11].
The clinical manifestations of onchocerciasis are di-
vided into dermal changes, lymphatic alterations and
ocular lesions. The prepatent period ranges from 3 to
15 months. While the microfilariae still are alive under
the subcutaneous tissue they do not trigger an inflam-
matory reaction. Itching is the first manifestation (iso-
lated or associated with skin lesions) that may be
troublesome and even irresistible, and scratching leads
to a picture of filarial scabies as it can be confused with
scabies, especially in countries where suspicion of on-
chocerciasis does not arise. In Africa these lesions
mainly affect the lumbar region, buttocks, thighs and
legs. In African patients there are two major changes. In
the so-called “lizard skin”, the skin dries, hardens and
peels (keratin layers), and the elastic fibres of the dermis
are lost thus giving the appearance of ageing. “Leopard
skin” occurs in chronic patients, where loss of melanin
leads to large depigmented spots with black dots indicat-
ing hair follicles and pores, particularly patent on the calfs.
Lymphatic manifestations include swollen lymph glands,
lymphadenitis, hanging groin due to chronic inflammation
and fibrosis that impair the lymph circulation. Complica-
tions include hernias (inguinal or femoral), and usually
affect the scrotum. Some atypical clinical manifestations
have been described such as abscesses around the anus or
in the groin [12, 13].
Ocular manifestations range from mild to total blind-
ness (white eyes). They can affect any area of the eye and
are only reversible in the initial phase of the ocular inva-
sion. Early signs are night blindness (hemeralopia), and
photophobia, with a bilateral decrease in daytime vision.
The discovery of Wolbachia and its importance in the
development of symptoms in onchocerciasis [14] raised
the possibility of eliminating the bacteria with antibiotics
to indirectly kill the filariae. The use of tetracyclines
(doxycycline) was demonstrated as effective [15], but re-
quires four to six weeks of treatment and is contraindi-
cated in children, pregnant or breastfeeding women.
With the aim to develop new drugs against onchocercia-
sis and other filariasis the “Anti-Wolbachia” consortium
was created in 2007 [16].
The clinical diagnosis of onchocerciasis is based on phys-
ical examination for onchocercomas, and the presence of
skin, lymph and eye disorders. The onchocercomas are
only detectable by palpation over flat bones; to detect those
at deeper locations imaging techniques are required. The
low sensitivity of nodule palpation indicated that is an un-
reliable method in areas with low prevalence; the value of
this method is too low to be capable of supporting an epi-
demiological decision [17]. In experimentally infected Pan
troglodytes many adult O. volvulus lie in deep tissues where
they are impalpable. Sites of preference were posterior to
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the hip joint, adjacent to the joint capsule, against the shaft
of the humerus and near the lesser trochanter [18].
In African patients skin biopsy from the buttocks, not
popular among patients, is recommended for diagnosis of
microfiladermia. It has limitations since in advanced and
chronic cases the microfilariae are in deep layers of the
dermis, therefore leading to false negatives. The Mazzoti
test is an indirect diagnosis that involves giving the patient
a small dose of ivermectin and noting adverse reactions. It
was replaced by the less unpleasant OCP-patch with DEC
(diethylcarbamazine) that induces a local inflammatory re-
action. A new developed ready-to-use format (LTS-2
patch) avoids the previous labour-intensive preparation
allowing large-scale use [19] Ultrasonography (USG) has
been evaluated for the detection of changes in the oncho-
cercomas after treatment [20], and may be used as an
adjunct to histological examination as it can even pick up
adults moving within them. Enzyme linked immunosorb-
ent assay (ELISA) for antibody detection is unable to dis-
tinguish an infection that has already been eliminated
from one that is active; however, it can be effectively used
to monitor the success of onchocerciasis elimination pro-
grams in Africa [21].
Rapid-format antibody cards for IgG4 which require
only a drop of blood showed a sensitivity of 90.6 % [22].
It is a fast procedure, easy to use, and less painful for pa-
tients than the skin-snip test. Various molecular diag-
nostic techniques have been developed, qPCR in dried
skin snips proves to be more sensitive than skin biopsy,
but the two tests should be combined to be certain [23].
Control is based almost exclusively on large-scale
treatment with ivermectin (Community Directed Treat-
ment with Ivermectin, CDTI) given annually or every six
months to the eligible members of the high risk commu-
nities. Although it was once believed that this measure
would be insufficient, elimination has been achieved by
long term CDTI alone in villages of Senegal, Mali and
Sudan, reviving debate on the eradicability of onchocer-
ciasis in Africa [24]. There are also studies showing the
ineffectiveness of monitoring strategies despite repeated
ivermectin treatment and vector control [25]. Clinical
trials have demonstrated that moxidectin can be a po-
tential alternative to ivermectin for its higher and pro-
longed efficacy, which results in almost full, year-long
suppression of microfilaridermia [26].
Mozambique has an estimated population of more
than 27 million and is divided into 11 provinces. Primary
health care is delivered through rural health centres that
typically cover an area of eight square kilometres,
though mobile healthcare agents may cover more than
50 square kilometres. Staffed by one or two general phy-
sicians, they cover 165 populations of 50,000 to 900,000
and provide basic laboratory services and simple radi-
ology. Some centres have basic laboratory services, such
as faecal examination for parasite infection detection.
None of these clinics have staff trained to perform skin
biopsies to confirm the diagnosis of onchocerciasis, since
it is an under-recognised problem in the country. Sec-
ondary health care is delivered by district hospitals, to
which more complex cases are referred. There is no sur-
veillance or control programme for onchocerciasis. The
disease is well reported in neighbouring Tanzania and
Malawi with 3,437,030 and 2,215,041 people, respect-
ively, requiring preventive chemotherapy in 2014 ac-
cording to the WHO. Areas surrounding Rivers Milange
and Muloza in Malawi serve as breeding sites for Simu-
lium damnosum [27]. In the districts of Thyolo and
Mwanza, onchocerciasis prevalences in the past were
29.4 % and 28.5 %, respectively [28, 29].
The objective of this paper is to summarise and critic-
ally review the available data about onchocerciasis in
Mozambique, to raise awareness of the existence and
importance of the disease, and to define research prior-
ities in terms of epidemiology, diagnosis, clinical mani-
festations, treatment, control, and economic and social
impact of this disease.
Methods and Results
The first surveys
The first report on the existence of onchocerciasis in
Mozambique was done by Noormahomed & Pividal in
1997 [30] and sponsored by the TDR-WHO in order to
confirm the presence of this parasitic condition in the
country and the possible occurrence of autochthonous
transmission in the Milange District (Zambezia Province).
There were two main reasons for choosing Milange Dis-
trict as a pilot study site: (i) Milange District borders
Malawi along the Muloza River for 223 km and is known
to be the breeding site for the vectors Simulium spp.; and
(ii) during the civil war that affected Mozambique from
1976 to 1992 there was a migration of populations from
Zambezia Province into Malawi, where endemic regions
of onchocerciasis, were identified [28, 29].
In Milange District 316 people were recruited at the rural
hospital of Milange. Most (98 %) of those studied were
males over 20 years of age. After performing a clinical
examination of the entire body, two skin snips were taken
from the posterior iliac crest, using a Holth sclerocorneal
punch, and placed immediately in microtiter plates with
200 μl of isotonic saline (NaCl 0.9 %).
Microscopic readings were made after 6 and 12 h and
the number of microfilaria per field were counted. A
symptom screening questionnaire was also completed by
all participants. Of the total sample, 45 individuals were
found to be infected, equivalent to an overall prevalence
of 14 %. Three of the 45 positive cases denied ever hav-
ing been in Malawi. The overall intensity of infection
was light; 7.5 expressed by the mean number of
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microfilariae per mg of skin. These preliminary screen-
ing results confirmed for the first time that both autoch-
thonous and imported onchocerciasis exists in
Mozambique, and, as such, represented a potentially sig-
nificant public health problem.
A second study (previously unpublished) was under-
taken in 1998 by Dr E. Noormahomed in different vil-
lages of Milange (Zambezia Province) and in the
Mecanhelas District (Niassa Province), also bordering
Malawi. The aim of this follow-up study was to better
clarify the variance in clinical presentation of onchocer-
ciasis and the differences related to the epidemiological
and parasitological findings. After obtaining informed
consent 370 people were screened in 6 different villages.
Similar to the first study, the screened individuals were
adults over 20 years of age, the majority being male. Of
those 141 (38.1 %) were not refugees. The screening
showed that 196 (53 %) patients were positive for O. vol-
vulus microfilariae based on skin biopsy, 120 (32.4 %)
had visible or palpable nodules and 102 (27.5 %)
expressed complaints about visual impairment (Table 1).
The patients screened exhibited typical findings for
onchocerciasis infection: the characteristic skin nodules
were variably present above and below the hip, with skin
depigmentation and dermatitis resembling scabies. Atyp-
ical dermal findings showing erythematous plaques of ir-
regular contour distributed in the body are displayed in
Fig. 1; investigation of these unusual manifestations was
considered necessary. This screening clearly indicated
that the detection of nodules by palpation is an inad-
equate method for diagnosis since 196 (53 %) patients
were detected by skin biopsy, of which only 120
(32.43 %) showed palpable nodules. Thus, 38.7 % of
cases (76 patients) would have remained undiagnosed if
we had only used palpation as a method of detection.
REMO surveys
Based on these preliminary data, the African Programme
for Onchocerciasis Control (APOC) sponsored the first
REMO in 2001 [31] in order to have a clear understand-
ing of the distribution and endemicity level of the
disease in Mozambique, so that appropriate measures
could be implemented. A total of 282 villages were
selected from eight out of the ten provinces in
Mozambique, namely: Niassa, Cabo Delgado, Nampula,
Zambezia, Tete, Manica, Sofala and Inhambane, according
to the REMO protocol (and other technical criteria) since
the population has been migrating in and out of neigh-
bouring countries over the last 2–3 decades due to war.
REMO was successfully carried out in 198 of the 282
villages selected, and a total of 7,270 people were
screened for palpable nodules. This report did not indi-
cate the sex or age of people, only that is was conducted
Table 1 Results obtained in the villages of Mozambique screened for O. volvulus in 1998 by E. Noormahomed
Village People examined Skin nodulesa Positive skin biopsyb Visual impairmentc Natives of Mozambiqued
Chizongo 120 33 (27.7) 60 (50.0) 26 (21.7) 34 (28.3)
Mambucha 44 15 (34.1) 26 (59.1) 15 (34.0) 6 (13.6)
Nambuzi 36 7 (19.4) 19 (52.8) 10 (27.7) 33 (91.6)
Vulalo 57 29 (51.0) 32 (56.1) 11 (19.3) 12 (21.0)
Matage 42 16 (38.1) 22 (52.3) 16 (38.1) 2 (4.7)
Mecanhelas 71 17 (24.0) 35 (49.3) 16 (22.5) 49 (69.0)
Total 370 120 (32.4) 196 (53) 102 (27.5) 141 (38.1)
aNumber (%) of people with nodules; bNumber (%) of people showing microfilaria in skin biopsy; cNumber (%) of people that expressed complains about visual
impairment; dNumber (%) of people who are not refugees from other countries
Fig. 1 Some microfiladermia-positive individuals exhibited atypical
dermal findings with erythematous plaques of irregular contour
irregularly distributed on the trunk, extremities, and even on the face
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in “randomly chosen adults”. In the selected villages of
Nampula, Manica and Sofala no onchocercomas were
found. Only 50 positive cases were found in thirty vil-
lages; 2 in Inhambane and Tete, 11 in Niassa, 18 in
Zambezia and 19 in Cabo Delgado. Nodule incidence
was between 1.0–9.0 % in 28 villages and between 10.0–
15.2 % in 2 villages. The REMO report concluded that
the positive cases of Onchocerca nodules from Zambezia
could be a spillover of infection from the neighbouring
Malawi focus. It was concluded that the Niassa focus
could be independent of the Tanzania side, but that this
needed further investigation [31].
The second REMO [30] took place six years later
(2007) to re-evaluate the status of the disease in relation
to the findings of 2001 study that rated the disease as
hypoendemic [31]. Based on the 2001 REMO survey that
demonstrated the existence of the disease, and suitable
ecology, combined with the continuous population mi-
gration mentioned previously this study was restricted
only to Niassa, Cabo Delgado, Zambezia and Tete. A
total of 114 villages were selected, amongst which 97
were successfully screened. A total of 3,780 consenting
adults were examined for O. volvulus nodules. Most of
the participants (86.96 %) were male. The results dem-
onstrated that 61 people (1.6 %) from the four provinces
showed characteristic onchocercomas. Of the 40 villages
with people positive for O. volvulus nodules, a nodule
rate of 1–9 % was observed and only two had a nodule
rate varying between 10 and 19 %. Three villages
(Mambucha, Vulalo and Matege) were visited in Niassa
Province, and although Noormahomed found high nod-
ule rates (34 %, 51 % and 38 %, respectively) in 1998,
only one infected person (out of 30 examined) was
found in Vulalo.
The REMO report [30] concluded that onchocerciasis
exists in Mozambique but is hypoendemic and indicated
that in Niassa there seems to be a focal area between
Maniamba and Lussimbesse, where a small cluster of vil-
lages had positive cases. Based on these results this REMO
study recommended further entomological studies and
parasitological investigation, including standardised skin
snips to determine the extent of the infection, and envis-
aged some clinic based treatment with ivermectin for the
present cases and others that may be detected.
Discussion
The presence of autochthonous and imported onchocer-
ciasis cases was evidenced in five provinces of
Mozambique: Niassa, Cabo Delgado, Zambezia, Tete
and Inhambane. The four diagnostic studies demon-
strated important differences in design which can poten-
tially explain the divergence in findings. The use of skin
biopsy and a symptom screening questionnaire com-
bined with nodule rate incidence in the first two surveys
(1997/98) may have captured even atypical or subacute
clinical presentations. Both REMO studies relied solely
on detection of palpable O. volvulus nodules. Taking into
consideration the results of Noormahomed in 1998, at
least 38.7 % of cases would have remained undiagnosed
in REMO studies. Measurement error in nodule preva-
lence has been subsequently confirmed in larger studies
by other authors detecting a significant variation be-
tween geographical regions [32]. Skin biopsy, although
superior to palpation, is also insensitive, as has been
shown using additional qPCR [23].
It is important to emphasise that between the two
REMO (six years apart), the prevalence of nodules de-
tected had more than doubled (from 0.69 % to 1.6 %). In
both interventions, positive cases were in the villages of
Niassa, Zambezia Cabo Delgado and Tete. The question
that arises from these results, after a further eight years
have almost elapsed is: “What is the current prevalence
in these villages?”
The culture and local languages of northern
Mozambique and Malawi are similar, no visa is needed
and immigration control is lax. The social and cultural
ties of the populations in the Northern provinces, and
their kith and kin in the neighbouring countries, in-
crease the likelihood that the disease will establish itself
in Mozambique. A great number of refugees left
Mozambique for Malawi during the civil war (1976–
1992), and many have since returned. Some may have
lived in endemic areas where they were exposed to and
likely infected by O. volvulus. The return of refugees and
the mixing of populations from both countries has
meant that infected people, whether due to autochthon-
ous or allochthonous exposure to onchocerciasis, are
found in Mozambique.
After some years of controlling leprosy and declaring it
no more a public health problem in 2010, Mozambique is
now witnessing an increase in the number of cases, espe-
cially in the Nampula Province [33]. It is surprising that
Nampula was reported in the first REMO as not having
onchocerciasis, though this province has the most cases of
leprosy in the country, with a prevalence of 0.006 %
among inhabitants in 2014, (0.013 % in some districts),
and no clear reason has emerged to explain this high
prevalence (data from the Ministry of Health of
Mozambique 2014). It is possible that some of these cases
may in fact represent unrecognised cases of onchocercia-
sis that fail to improve despite being subjected to treat-
ment against leprosy. Some health workers reported
“atypical” cases of leprosy, in which patients present with
skin sensitivity and no improvement after completing the
leprosy treatment. We believe that these cases might be
misdiagnosed cases of onchocerciasis. Those patients with
a diagnosis of leprosy may also have been absent from the
study population since stigmatisation from their leprosy
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diagnosis might lead to isolation. The provinces of Zam-
bezia, Cabo Delgado, Niassa and Manica are also the most
affected ones with leprosy. Those provinces, except Man-
ica, are the ones where REMO 2 detected cases of oncho-
cerciasis, with the possibility that some patients with
nodules and skin disorders were confused and treated as
leprosy patients. The two conditions may even present at
the same time, in which case the diagnosis will be of lep-
romatous leprosy, because onchocerciasis is not recog-
nised by health professionals.
Scabies is another condition that generates dermal
changes such as an irresistible itch. Patients diagnosed with
scabies, but who do not respond to treatment with hex-
ochloride benzene, may actually be infected with onchocer-
ciasis. The possible relationship between onchocerciasis
with epilepsy also needs to be investigated in Mozambique.
During our first screening study, most patients were
unaware of the cause of the disease while others strongly
believed that it was a disease caused by spirits. This be-
lief was reinforced as secondarily infected nodules re-
solved with traditional treatment. Visual impairment
characteristic of onchocerciasis was not a prevalent find-
ing, however in the study of 1998 (Table 1) 102 patients
with positive skin biopsy reported visual impairment. A
family of two with this symptomatology and microfila-
dermia was found during the first study although no
member was blind.
Unresolved issues remain concerning transmission, es-
pecially near to the breeding sites of autochthonous
Simulium spp. The results of a geostatistical analysis
of all the REMO data [34] showed clearly that
Mozambique has borders with two high-risk areas of
onchocerciasis located in Tanzania and Malawi. The
authors of this analysis indicated textually: “In Gabon
and Mozambique only 0.3 % of the surface was classi-
fied as a high risk area. In both cases, it concerned a
narrow border area where no REMO surveys were
done within the country itself but where the presence
of a large endemic focus on the other side of the border in
the neighbouring country suggests that there may be also
some hyperendemic villages on the banks of the border
river within Gabon and Mozambique. Except for those nar-
row border areas, the REMO data for these two countries
do not indicate the presence of any high risk areas”. Obvi-
ously in the case of Mozambique reference of the experts
should refer the Ruvuma River which marks the border
with Tanzania. There are large and small rivers in the
northern provinces of Mozambique with many potential
breeding sites for blackflies. There are reports referring to
the River Muloza as a vector-breeding site. The presence of
onchocerciasis and the vector were demonstrated years ago
in the districts of Mwanza, Thyolo and Mulanje (Malawi)
[28, 29]. Mulanje is just over 40 km from the Mozambique
border. Given that Simulium spp. can easily travel long
distances it is likely that the vector crosses the border into
Mozambique or breeds along that same border inside
Mozambique.
Conclusions
The studies analysed here provided evidence of the exist-
ence of onchocerciasis in Mozambique, although it is
hypoendemic. As the rural population moves frequently
from one place to another, it is possible that the distri-
bution of the disease has changed since the last REMO
performed in 2007. Based on the preliminary data, on-
chocerciasis may be present at least in five provinces of
Mozambique. Targeted epidemiological surveillance is
needed to monitor that the disease is not spreading to other
provinces, given that the vector can fly long distances.
To date little is known about the epidemiology and
clinical aspects of the disease in Mozambique or its
transmission patterns. The risk factors need to be identi-
fied and validated, and vulnerable populations and geo-
graphic areas identified as priorities for further research
and targeting of surveillance activities. Seroepidemiologi-
cal and parasitological investigations, using antigen de-
tection cards and standardised skin snips, should be
carried out in focal areas to determine the extent of the
infection. These measures will contribute to the entry of
potential onchocerciasis patients into the health care
system for appropriate treatment and care. There is no
awareness of the clinical aspects of the disease, differen-
tial diagnosis with lepromatous leprosy and dermatitis
caused by Scabies scabiei needs to be addressed by train-
ing health professionals in the recognition of this dis-
ease. It has been suggested that the infection by O.
volvulus can be associated with epilepsy, and if so, a
study would be required to determine the proportion of
epilepsy sufferers that are infected. There is an ongoing
program in Mozambique (2012–2016) for controlling
neglected tropical diseases, including schistosomiasis,
lymphatic filariasis and soil transmitted helminths. Mass
drug administration is conducted every year to more
than 500,000 people [35]. We must prioritise studies
designed to understand clinical and epidemiological
aspects of onchocerciasis and its distribution, the effi-
cacy of mass drug treatment, and if there is emerging
ivermectin resistance. Entomological samples should
be taken in Cabo Delgado, Niassa, Nampula, Zambezia,
Tete and Manica, in order to explore the existence or
otherwise of anthropophilic black flies and studies
should be carried out to ascertain their capacity as
vectors. As was indicated in 2014 (44) the first step
in the implementation of REMO in each country in-
volved the identification of possible areas that are un-
suitable for onchocerciasis transmission, and where,
therefore, no further surveys were required. So, the
identification in Mozambique of suitable and unsuitable
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areas for Simulium spp. breeding will be a priority. Future
investigation should therefore establish whether or not the
vectors breed in the rivers of Mozambique.
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